Head and neck cancer was last reviewed in the Journal in 19831. At that time, there was
promising new information on a possible role for chemotherapy1, 2. During the past decade …

Head and neck cancers include neoplasms of the oral cavity, pharynx, and larynx. The risk
of these cancers is strongly associated with smoking and alcohol ingestion. There have …

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to
practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy …

Background The effect of the addition of adjuvant chemotherapy to concurrent
chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. We …

Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the
benefit of adding chemotherapy to radiation in patients with unresectable squamous cell …

Background Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil
(PF) plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head and …

PURPOSE The Southwest Oncology Group (SWOG) conducted a randomized comparison
of cisplatin plus fluorouracil (5-FU) and carboplatin plus 5-FU versus single-agent …

ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively
replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX …

PURPOSE A prospective randomized multicenter trial was performed to evaluate the
contribution of simultaneously administered chemotherapy (CT) and radiotherapy (RT) in …

Purpose To compare the antitumor activity and toxicity of the two induction chemotherapy
treatments of paclitaxel, cisplatin, and fluorouracil (FU; PCF) versus standard cisplatin and …